1st Quarter - Report

INVITROGEN CORPORATION for INVITROGEN CORPORATION

Period 1st Quarter 2008 Filed Apr 20, 2008 Signed by Janet Lynch Lambert, V.P. Government Relations, Invitrogen Corp

Official filing
Firm
INVITROGEN CORPORATION
Client
INVITROGEN CORPORATION
Income
—
Expenses
$160,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R 493, S 258, HR 1424, Genetic Information Nondiscrimination Act (GINA) - in favor S.3822, the Genomics and Personalized Medicine Act - re: regulatory, reimbursement, and incentive provisions

LobbyistCovered position, as disclosed
JANET LYNCH LAMBERT AA & LD, Rep. Peter Kostmayer (88-92)

Bills named: S. 3822 (110th), H.R. 493 (110th), H.R. 1424 (110th)

Budget/Appropriations BUD

H. Con Res. 312/ S. Con Res. 70 - FY09 Budget Resolution - re higher domestic discretionary budgets/biomedical research LHHS FY09 Appopriations (not yet numbered) - re: NIH funding, BARDA FY09 Supplemental Appropriations (not yet numbered) - re: biomedical research funding (NIH, BARDA) DoD FY09 Appropriations (not yet numbered) - re biodefense funding

LobbyistCovered position, as disclosed
JANET LYNCH LAMBERT AA & LD, Rep Peter Kostmayer (88-92)

Bills named: H.Con.Res. 312 (110th), S.Con.Res. 70 (110th)

Copyright/Patent/Trademark CPT

S. 1145 - Patent Reform Act - related to research use exceptions, and modifications to major provisions of the patent reform bill

LobbyistCovered position, as disclosed
JANET LYNCH LAMBERT AA & LD, Rep Peter Kostmayer (88-92)

Bills named: S. 1145 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.